NCT03168828View on ClinicalTrials.gov

Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

April 24, 2017

Primary Completion Date

July 26, 2018

Study Completion Date

July 26, 2018

Conditions
Neurogenic Detrusor Overactivity
Interventions
DRUG

Trospium-Releasing Intravesical System (TAR-302-5018)

TAR-302-5018 is a passive, nonresorbable trospium-releasing intravesical system whose primary mode of action is the controlled release of trospium into the bladder over a 42-day period.

Trial Locations (4)

23462

Urology of Virginia, Virginia Beach

28207

Carolinas HealthCare System, Charlotte

48084

Michigan Institute of Urology, Troy

98101

Virginia Mason, Seattle

All Listed Sponsors
lead

Taris Biomedical LLC

INDUSTRY

NCT03168828 - Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury | Biotech Hunter | Biotech Hunter